PKM and non-small cell lung carcinoma: However, SMI treatment showed a significant decrease in immunostaining for PKM2 in the cytoplasm (≤ 1+) with a concomitant increase of immunostaining in nuclei (≥2+) of established NSCLC cell lines (Fig 4B and S3 Table).